Rapid Micro Biosystems Inc (RPID) - Total Liabilities
Based on the latest financial reports, Rapid Micro Biosystems Inc (RPID) has total liabilities worth $41.97 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Rapid Micro Biosystems Inc - Total Liabilities Trend (2010–2025)
This chart illustrates how Rapid Micro Biosystems Inc's total liabilities have evolved over time, based on quarterly financial data. See RPID working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Rapid Micro Biosystems Inc Competitors by Total Liabilities
The table below lists competitors of Rapid Micro Biosystems Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ahn-Gook Pharmaceutical Co. Ltd
KQ:001540
|
Korea | ₩136.13 Billion |
|
APEX International Financial Engineering Res & Tech Co Ltd
TWO:5210
|
Taiwan | NT$77.78 Million |
|
Panin Sekuritas Tbk
JK:PANS
|
Indonesia | Rp1.28 Trillion |
|
Tailyn Technologies
TWO:5353
|
Taiwan | NT$630.22 Million |
|
AB Kauno Energija
STU:WVJ
|
Germany | €111.17 Million |
|
Tacheng Real Estate Co Ltd
TWO:6171
|
Taiwan | NT$1.79 Billion |
|
Courtside Group, Inc. Common Stock
NASDAQ:PODC
|
USA | $8.94 Million |
|
Ardea Resources Ltd
AU:ARL
|
Australia | AU$28.99 Million |
Liability Composition Analysis (2010–2025)
This chart breaks down Rapid Micro Biosystems Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Rapid Micro Biosystems Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.67 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Rapid Micro Biosystems Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Rapid Micro Biosystems Inc (2010–2025)
The table below shows the annual total liabilities of Rapid Micro Biosystems Inc from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $41.65 Million | +82.52% |
| 2024-12-31 | $22.82 Million | -10.39% |
| 2023-12-31 | $25.46 Million | -3.84% |
| 2022-12-31 | $26.48 Million | +31.17% |
| 2021-12-31 | $20.19 Million | -55.31% |
| 2020-12-31 | $45.18 Million | +39.38% |
| 2019-12-31 | $32.41 Million | +374.15% |
| 2011-12-31 | $6.84 Million | +36.12% |
| 2010-12-31 | $5.02 Million | -- |
About Rapid Micro Biosystems Inc
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biologics, medical devices, and personal care products in the United States, Switzerland, Germany, Japan, and internationally. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, … Read more